This slideshow reviews drug information for opdivo nivolumab indicated for metastatic squamous non small cell lung cancer nsclc table of contents. For adults with metastatic melanoma opdivo r nivolumab is a prescription medicine used to treat a type of skin cancer called melanoma that has spread or cannot be removed by surgery advanced melanoma opdivo is approved for both braf and braf patients. Nivolumab approved for metastatic lung cancer on march 4 2015 the fda approved a new indication for nivolumab for the treatment of patients with metastatic squamous non small cell lung cancer nsclc that had progressed with platinum based chemotherapy. Opdivo is currently approved as a single agent and in combination with yervoy for patients with metastatic melanoma additionally the agent is approved for patients with non squamous and squamous nsclc and for those with metastatic rcc. On march 4 2015 the anti programmed cell death protein 1 pd 1 monoclonal antibody nivolumab opdivo was granted approval for treatment of patients with metastatic squamous non small cell lung cancer nsclc with progression on or after platinum based chemotherapy 12 nivolumab was previously approved in december 2014 for treatment of
How it works:
1. Register Trial Account.
2. Download The Books as you like ( Personal use )